Dovlatova, N L <br/><br/>
The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.  [electronic resource] 

 -  Journal of thrombosis and haemostasis : JTH  Jul 2008 
 - 1153-9 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1538-7836 
<br/><br/><label>Standard No.: </label>10.1111/j.1538-7836.2008.03020.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenosine Diphosphate--pharmacology<br/>Adenosine Monophosphate--analogs & derivatives<br/>Blood Platelets--drug effects<br/>Cells, Cultured<br/>Clopidogrel<br/>Drug Interactions<br/>Humans<br/>Piperazines--metabolism<br/>Platelet Aggregation Inhibitors<br/>Platelet Function Tests<br/>Prasugrel Hydrochloride<br/>Purinergic P2 Receptor Antagonists<br/>Receptors, Purinergic P2Y12<br/>Thiophenes--metabolism<br/>Ticlopidine--analogs & derivatives